NORD and 27 organizations endorse model legislation on biomarker access to the National Council of Insurance Legislators
Published: Jun 7, 2022
Tagged in: Genetic Testing, Access to Diagnostics, Access to Innovative Medicines and Therapies
For decades, NORD has pursued federal and state policies that will change the lives of Americans impacted by rare diseases for the better. NORD’s work can be viewed below. This page is updated daily to provide timely information. Please contact us if you have questions or need additional information.
NORD and 27 organizations endorse model legislation on biomarker access to the National Council of Insurance Legislators
Published: Jun 7, 2022
Tagged in: Genetic Testing, Access to Diagnostics, Access to Innovative Medicines and Therapies
NORD and 21 organizations send letter to House Energy and Commerce Committee leadership to support the NIH Clinical Trial Diversity Act
Published: Jun 9, 2022
Tagged in: Clinical Trials, Rare Disease Clinical Trials
NORD and 84 organizations urge Senate HELP leadership to incorporate the RARE Act into the FDA Safety and Landmarks Advancement Act
Published: Jun 3, 2022
Tagged in: RARE Act, Orphan Drug Act, Protecting FDA Standards for Safe and Effective Drugs
NORD and 73 organizations urges CMS to reinstate step therapy prohibition in Medicare Advantage plans for Part B drugs
Published: May 31, 2022
Tagged in: Access to Innovative Medicines and Therapies, Medicare, Medicaid, and Private Health Insurance Coverage
NORD and 75 organizations urge Congress to support step therapy reform
Published: May 24, 2022
Tagged in: Access to Innovative Medicines and Therapies